FDA Comes Out Against Aspirin To Prevent First Heart Attacks

In the latest development in a long-simmering debate, the FDA has announced that aspirin should not be marketed for the prevention of a first heart attack or stroke in people with no history of cardiovascular disease. The announcement follows FDA’s rejection on Friday of Bayer Healthcare’s decade-old  petition requesting approval of a primary prevention indication. [PDF of FDA rejection letter]

Click here to read the full post on Forbes.



  1. One key take-away from this article is that the FDA is noting that aspirin shouldn’t be “marketed” as a preventative step for heart disease in individuals who have no prior history. Physicians who are aware of a patient’s history may advise their patients to go on an aspirin regimen – which is very different from taking advice from a television commercial or print ad to begin taking aspirin to improve heart health.

Speak Your Mind